Department of Pharmacology and Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
Department of Pediatrics, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
Int J Risk Saf Med. 2021;32(4):279-293. doi: 10.3233/JRS-200058.
Off-label drug (OLD) use is common in neonates.
There is a dearth of information associating the OLD use and the risk of medication errors in critically ill neonates. Hence, the present study was carried out.
Drug prescriptions in neonates admitted to the intensive care unit of a tertiary care hospital between September 2018 and June 2019 were evaluated. Details on their demographics, reason for admission in intensive care unit, drug-related information and serum creatinine were extracted. United States Food and Drug Administration approved drug labels were compared. World Health Organization (WHO) anatomy, therapeutic and chemical (ATC) classification was used for drug categorization. We assessed the risk of medication errors in the adult population using a validated tool: medication risk score (MERIS).
One hundred and seventy-one neonates with 2394 prescriptions were included in this study. Seventy one percent of the neonates in the present study received at least one OLD/unlicensed prescription item. A trend in increased numbers of OLD/unlicensed drug use in more premature and lower birth weight neonates were observed. Medication risk score was significantly higher in neonates receiving OLD/unlicensed drugs compared to those with only labelled drugs. Very and extreme pre-term (along with very low and extremely low birth weight) neonates were at higher risk of medication errors compared to others. Presence of OLD/unlicensed prescribed items is associated with a potentially increased risk of medication errors by an odds ratio of 20.4 compared to labelled drugs.
Significant proportions of critically ill neonates received at least one OLD/unlicensed drug and such use was associated with potentially increased risk of medication errors.
超适应证用药(OLD)在新生儿中较为常见。
目前,关于危重新生儿中 OLD 用药与药物错误风险的相关信息十分匮乏。因此,开展了本研究。
评估了 2018 年 9 月至 2019 年 6 月期间入住三级医院重症监护病房的新生儿的药物处方。提取了其人口统计学、入住重症监护病房的原因、药物相关信息和血清肌酐等详细信息。将美国食品和药物管理局批准的药物标签进行了比较。采用世界卫生组织(WHO)解剖、治疗和化学(ATC)分类对药物进行了分类。我们使用经过验证的工具(药物风险评分[MERIS])评估了成人的药物错误风险。
本研究共纳入 171 例新生儿,共 2394 份处方。本研究中 71%的新生儿至少接受了一种 OLD/无许可证处方药物。观察到早产儿和低出生体重儿的 OLD/无许可证药物使用数量呈增加趋势。与仅使用标签药物的新生儿相比,接受 OLD/无许可证药物的新生儿的药物风险评分显著更高。与其他新生儿相比,非常早产和极早产(以及极低和超低出生体重)的新生儿发生药物错误的风险更高。与标签药物相比,使用 OLD/无许可证处方药物的新生儿发生药物错误的风险更高,比值比为 20.4。
相当比例的危重新生儿接受了至少一种 OLD/无许可证药物,此类药物的使用与药物错误风险增加有关。